Company profile: ZyVersa Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics for inflammatory and renal diseases, including IC 100, a monoclonal antibody targeting ASC in inflammasomes to inhibit the initiation and perpetuation of inflammatory diseases, and VAR 200, a cholesterol efflux mediator that removes excess cholesterol from the kidney's filtration system to reduce proteinuria and preserve kidney function.
Products and services
- VAR 200: A renal filtration-specific cholesterol efflux mediator that removes excess cholesterol from the kidney's filtration system to reduce proteinuria and preserve kidney function
- IC 100: An ASC-directed monoclonal antibody that targets ASC in inflammasomes to inhibit initiation and perpetuation of inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ZyVersa Therapeutics
Gambro
HQ: Sweden
Website
- Description: Provider of medical technology developing, manufacturing and supplying products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gambro company profile →
Talphera
HQ: United States
Website
- Description: Provider of therapies for the treatment of pain and other conditions, focusing on development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talphera company profile →
Renal Solutions
HQ: United States
Website
- Description: Provider of dialysis products and services, focused on their development. Founded in 2000 and based in Warrendale, Pennsylvania; acquired by Fresenius Medical Care in November 2007.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renal Solutions company profile →
Allena Pharmaceuticals
HQ: United States
Website
- Description: Provider of non-systemic protein therapeutics to treat metabolic and orphan diseases, engaged in development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allena Pharmaceuticals company profile →
Renibus Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renibus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ZyVersa Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ZyVersa Therapeutics
2.2 - Growth funds investing in similar companies to ZyVersa Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ZyVersa Therapeutics
4.2 - Public trading comparable groups for ZyVersa Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →